Difference between revisions of "Doxorubicin (Adriamycin)"
Warner-admin (talk | contribs) m (Text replacement - "{| border="1"" to "{| class="wikitable"") |
m |
||
Line 20: | Line 20: | ||
*[[Ewing's sarcoma]] | *[[Ewing's sarcoma]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
+ | *[[Hepatoblastoma]] | ||
*[[Hepatocellular carcinoma]] | *[[Hepatocellular carcinoma]] | ||
*[[HIV-associated lymphoma]] | *[[HIV-associated lymphoma]] | ||
Line 156: | Line 157: | ||
[[Category:Ewing's sarcoma medications]] | [[Category:Ewing's sarcoma medications]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
+ | [[Category:Hepatoblastoma medications]] | ||
[[Category:Hepatocellular carcinoma medications]] | [[Category:Hepatocellular carcinoma medications]] | ||
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] |
Revision as of 05:37, 30 September 2018
General information
Class/mechanism: Anthracycline; binds and intercalates into DNA, inhibiting nucleotide replication and DNA/RNA polymerase activity. Intercalation of DNA triggers DNA cleavage via topoisomerase II. Toxic effects on organs may be related to cell membrane lipid binding activities; enzymatic electron reduction of doxorubicin creates reactive species, e.g. hydroxyl free radicals OH-, which has been implicated in cardiotoxicity by means of Cu (II) and Fe (III) reduction.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adrenocortical carcinoma
- Adult T-cell leukemia-lymphoma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Cutaneous basal cell carcinoma
- Bladder cancer
- Breast cancer
- Burkitt lymphoma
- Chronic lymphocytic leukemia (CLL/SLL)
- Diffuse large B-cell lymphoma
- Ewing's sarcoma
- Follicular lymphoma
- Hepatoblastoma
- Hepatocellular carcinoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Multiple myeloma
- Osteosarcoma
- Pancreatic NET
- Peripheral T-cell lymphoma
- Post-transplant lymphoproliferative disorder
- Primary mediastinal B-cell lymphoma
- Renal cell carcinoma
- Soft tissue sarcoma
- Small cell lung cancer
- Cutaneous squamous cell carcinoma
- Thymoma
- Transformed lymphoma
- Transplant conditioning regimens
- Uterine cancer
- Vascular sarcoma
- Waldenström macroglobulinemia
Patient drug information
- Doxorubicin (Adriamycin) patient drug information (Chemocare)[3]
- Doxorubicin (Adriamycin) package insert page 1[1]
- Doxorubicin (Adriamycin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 8/7/1974: Initial FDA approval
- 5/8/2003: Earliest date with label information at Drugs @ FDA: "Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
Also known as
- Generic name: hydroxydaunorubicin
- Brand names:
Synonyms | |||||||
---|---|---|---|---|---|---|---|
Adriablastina | Adriacept | Adriacin | Adriamycin | Adriblastin | Adriblastina | Adriblastine | Adricept |
Adricin | Adrim | Adrimedac | Adrosal | Antraciclin | Biorrub | Biorubina | Cadria |
Carcinocin | Cloridrato DE | Doxorrubicina Colhidrol | Daxotel | Deldoxin | Dicladox | Dobicin | Dobixin |
Doxo | Doxobin | Doxo Cell | Doxocris | Doxokebir | Doxolem | Doxonolver | Doxor |
Doxorrubicina | Doxoruben | Doxorubicina | Doxorubicine | Doxorubicinum | Doxorubin | Doxotec | Doxtie |
Duxocin | Evacet | Farmiblastina | Fauldoxo | Flavicina | Ifadox | Kemodoxa | Lipodox |
Lyphidox | Myocet | Nagun | Neoxane | Nuaze | Oncodria | Onkodox | Onkostatil |
Pallagicin | Ranxas | Rastocin | Ribodoxo | Roxorin | Rubex | Varidoxo | Zodox |
References
- Drugs
- Intra-arterial medications
- Intravenous medications
- Intravesical medications
- Vesicant chemotherapy
- Anthracyclines
- Topoisomerase inhibitors
- Adrenocortical carcinoma medications
- Adult T-cell leukemia-lymphoma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Cutaneous basal cell carcinoma medications
- Bladder cancer medications
- Breast cancer medications
- Burkitt lymphoma medications
- Chronic lymphocytic leukemia (CLL/SLL) medications
- Diffuse large B-cell lymphoma medications
- Ewing's sarcoma medications
- Follicular lymphoma medications
- Hepatoblastoma medications
- Hepatocellular carcinoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Multiple myeloma medications
- Osteosarcoma medications
- Pancreatic NET medications
- Peripheral T-cell lymphoma medications
- Post-transplant lymphoproliferative disorder medications
- Primary mediastinal B-cell lymphoma medications
- Renal cell carcinoma medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- Cutaneous squamous cell carcinoma medications
- Thymoma medications
- Transformed lymphoma medications
- Transplant medications
- Uterine cancer medications
- Vascular sarcoma medications
- Waldenström macroglobulinemia medications
- FDA approved in 1974
- WHO Essential Cancer Medicine